Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 120, Issue 1, 2011, Pages 18-22

  Kang, Sokbom ^a   Kim, Tae Joong ^b   Seo, Sang Soo ^a   Kim, Byoung Gie ^b   Bae, Duk Soo ^b   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

CA 125; Neoadjuvant chemotherapy; Optimal cytoreduction; Ovarian cancer; Risk factor

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 78649908312     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.09.024     Document Type: Article

References (23)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, and A. Ghafoor Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. D.S. Chi, J.B. Liao, L.F. Leon, E.S. Venkatraman, M.L. Hensley, and D. Bhaskaran Identification of prognostic factors in advanced epithelial ovarian carcinoma Gynecol Oncol 82 2001 532 537
3. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979 discussion 979-80
4. K.K. Shih, and D.S. Chi Maximal cytoreductive effort in epithelial ovarian cancer surgery J Gynecol Oncol 21 2010 75 80
5. P.E. Schwartz, J.T. Chambers, and R. Makuch Neoadjuvant chemotherapy for advanced ovarian cancer Gynecol Oncol 53 1994 33 37
6. P.E. Schwartz Neoadjuvant chemotherapy for the management of ovarian cancer Best Pract Res Clin Obstet Gynaecol 16 2002 585 596
7. T. Van Gorp, F. Amant, P. Neven, P. Berteloot, K. Leunen, and I. Vergote The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer Cancer Treat Res 134 2007 387 402
8. I. Vergote, T. van Gorp, F. Amant, P. Neven, and P. Berteloot Neoadjuvant chemotherapy for ovarian cancer Oncology 19 2005 1615 1622 (Williston Park, discussion 1623-30)
9. I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J. Decloedt, and P. van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
10. W. Kuhn, S. Rutke, K. Spathe, B. Schmalfeldt, G. Florack, and B. von Hundelshausen Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma Cancer 92 2001 2585 2591
11. K. Ushijima, S. Ota, K. Komai, G. Matsuo, S. Motoshima, and S. Honda Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer Int Surg 87 2002 185 190
12. Y.M. Chan, T.Y. Ng, H.Y. Ngan, and L.C. Wong Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study Gynecol Oncol 88 2003 9 16
13. P. Morice, D. Brehier-Ollive, A. Rey, D. Atallah, C. Lhomme, and P. Pautier Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study Ann Oncol 14 2003 74 77 (Pubitemid 36150262)
14. P.E. Schwartz, and W. Zheng Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis Gynecol Oncol 90 2003 644 650
15. E.N. Everett, A.E. French, R.L. Stone, L.M. Pastore, A.A. Jazaeri, and W.A. Andersen Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer Am J Obstet Gynecol 195 2006 568 574 discussion 574-6
16. A. Inciura, A. Simavicius, E. Juozaityte, J. Kurtinaitis, R. Nadisauskiene, and E. Svedas Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients BMC Cancer 6 2006 153
17. T. Le, G. Alshaikh, L. Hopkins, W. Faught, and M.F. Fung Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking Ann Surg Oncol 13 2006 1711 1716 (Pubitemid 44951481)
18. S.J. Lee, B.G. Kim, J.W. Lee, C.S. Park, J.H. Lee, and D.S. Bae Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery J Obstet Gynaecol Res 32 2006 99 106
19. H. Steed, A.M. Oza, J. Murphy, S. Laframboise, G. Lockwood, and D DEP A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer Int J Gynecol Cancer 16 Suppl 1 2006 47 53
20. J.Y. Hou, M.G. Kelly, H. Yu, J.N. McAlpine, M. Azodi, and T.J. Rutherford Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 2007 211 217
21. I. Vergote, C.G. Trope, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
22. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
23. S. Kang, T.J. Kim, B.H. Nam, S.S. Seo, B.G. Kim, and D.S. Bae Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis J Surg Oncol 101 2010 13 17